Figure 2.

DC3s Infiltrate Human Breast Tumors

(A) Representative gating strategy used to define macrophages, CD5⁺ cDC2s, and CD14⁺ DC3s and histograms showing the expression of CD163, FcεRI, BTLA, and CD11c in human breast cancer primary tumors.

(B) Violin plot quantifying cDC1, CD5⁺cDC2, CD14⁺ DC3, and CD14⁺CD88⁺ macrophage subsets identified in (A) in human breast cancer primary tumors (n = 25; ^∗p < 0.05, ^∗∗p < 0.01, ^∗∗∗p < 0.001, ^∗∗∗∗p < 0.0001, one-way ANOVA test).

(C) Pearson correlations of the frequencies of macrophages, cDC1s, CD5⁺cDC2s, and CD14⁺ DC3s within HLA-DR⁺ cells in human breast cancer primary tumors (red, significantly correlated p < 0.05; black, not correlated).

(D) HC showing the relative expression of markers used for subset identification in Figure 1 in CD1c⁺, CD1c⁺CD14⁺, and CD14⁺ cells from invaded lymph nodes draining human breast cancer primary tumors.

(E) GSEA of pairwise comparisons of CD1c⁺CD14⁺ cells with CD1c⁺ or CD14⁺ from invaded lymph nodes draining human breast cancer primary tumors. Gene signatures of blood DC3s compared with cDC2s (DC3 > cDC2) or CD14⁺ monocytes (DC3 > Mono) and, vice versa, of blood cDC2s (cDC2 > DC3) or CD14⁺ monocytes (Mono > DC3) compared with DC3s were used (Villani et al., 2017).

See also Figure S2 and Table S2.